HealthMore in Health→
Semaglutide Misses in Phase 3 Alzheimer’s Trials, Narrowing a Hoped-For New Path
Key Takeaways
- Phase 3 EVOKE(+) trials found semaglutide did not slow clinical progression of Alzheimer’s disease.
- Earlier preclinical, observational, and small trial signals had raised hopes for GLP-1 drugs in neurodegeneration.
- The negative result still helps refine future Alzheimer’s research around inflammation, vascular dysfunction, and metabolic pathways.
DE
DT Editorial Team··via nature.com
